Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Puma Biotechnology Q4 2023 Adj EPS $0.310 Beats $0.300 Estimate, Sales $72.200M Miss $73.550M Estimate

Author: Benzinga Newsdesk | February 29, 2024 05:15pm
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.310 per share which beat the analyst consensus estimate of $0.300 by 3.33 percent. The company reported quarterly sales of $72.200 million which missed the analyst consensus estimate of $73.550 million by 1.84 percent. This is a 9.89 percent increase over sales of $65.700 million the same period last year.

Posted In: PBYI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist